Skip to main content
Publications
Pladevall-Vila M, Ziemiecki R , Johannes CB , Khan AM , Mines D, Ebert N, Kovesdy CP, Thomsen RW, Baak BN, Garcia-Sempere A, Kanegae H, Coleman CI, Walsh M, Andersen IT, Bernal CR, Cabaninas CR, Christiansen CF, Farjat AE, Gay A, Gee P, Herings RMC, Hurtado I, Kashihara N, Kristensen FPB, Liu F, Okami S, Overbeek JA, Beest FJAP, Yamashita S, Yano Y, Layton JB , Vizcaya D, Oberprieler NG. Clinical profile and treatment patterns in individuals with type 2 diabetes and chronic kidney disease who initiate a GLP-1 receptor agonist: a multinational cohort study . Diabetes Ther. 2025 May;16(5):931-54. doi: 10.1007/s13300-025-01717-8
Rodriguez-Buritica DF, Dine J , Brown TM , Romano (DeMuro) C , Bratlee-Whitaker E , Ferrecchia I, Temkin G, Mora JJ, Babakhani RA, Ko JJ, Weinstein D. Qualitative interviews to support the development of a Patient-Reported Outcome (PRO) measure for glycogen storage disease type Ia . Poster presented at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting; March 18, 2025. Los Angeles, CA.
Paller AS, Siegfried EC, Marron SE, Clark M , Harris N , Kosa K , Qin S , Whalley D , Chao J, Bansal A, Chuang CC, Wang Z. Skin pain and sleep quality numeric rating scales for children aged 6 months to 5 years with atopic dermatitis . J Eur Acad Dermatol Venereol. 2025 Mar;39(3):e209-12. doi: 10.1111/jdv.20199
Weisel K, Mateos MV, Landgren O, Leleu X, Quach H, Bennett L , Talpes M, Majer I, Patel S, Usmani SZ. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with carfilzomib, dexamethasone, and daratumumab versus carflizomib and dexamethasone: an analysis of patient-reported outcomes from the phase 3 CANDOR trial . Clin Lymphoma Myeloma Leuk. 2025 Feb 19. doi: 10.1016/j.clml.2025.02.005
Hellwig K, Magyari M, MacDonald TM, Cesta CE, Wergeland S, Leinonen MK, Ornoy A, Vukusic S, Lauer A, Zhou X , Kawai A , Weinrib R , Arana A , Boumenna T. A multi-country cohort database study to assess pregnancy and infant outcomes after potential maternal or paternal exposure to cladribine tablets in the treatment of multiple sclerosis: the CLEAR study methods and status update1 . Ther Adv Neurol Disord. 2025 Jan 27;18:175628642. doi: 10.1177/17562864241310996
Blauvelt A, Reckleff J, Zhao Y, Clark M , Kosa K , Harris N , Esfandiari E, Martin S , Whalley D , Emma GY. Content evaluation of pruritus, skin pain, and sleep disturbance patient-reported outcome measures in adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews . Br J Dermatol. 2025 Jan 24;192(2):247-60. doi: 10.1093/bjd/ljae346
Romano (DeMuro) C , Bratlee-Whhitaker E , Hartry A, Mearns E, Taylor J, Taylor G, Callahan L, Monks D, Kremer I, Lappin D, Frangiosa T, Sangodkar S, Herring WL , Gnanasakthy K, Goss D , McLeod L , Edwards T , Poulos C , DiBenedetti D , Paulsen R. Measuring what matters most to people living with Alzheimer's disease and care partners: What Matters Most quantitative research development . Poster presented at the Alzheimer's Association International Conference (AAIC) 2024; July 31, 2024. Philadelphia, PA. [abstract] Alzheimers Dement. 2025 Jan 9; 20(S4):E085103. doi: 10.1002/alz.085103
Sutton Norman K , Zigler C, Brown M, Miller J, Bosworth H, Collyar D, Oakes M, Fowler V, Howard-Anderson J, Korn R, Ruffin F, Boucher H, Doemberg S, Reeve B, King H. Patient and clinician perspectives of care interactions for complicated urinary tract infections to inform implementation of patient-reported outcome measures: a qualitative descriptive study . Poster presented at the 17th Annual Conference on the Science of Dissemination and Implementation in Health; December 9, 2024. Arlington, VA.
Kosa K , Vanegas A, Colavecchia C, Coulter J, Christopher SA, Fasano RM, Chou ST, Drachtman RA, Purdie DM, Baker CL, Meier ER. Qualitative interview study to characterize the treatment experiences of participants with sickle cell disease and assess perceptions of red blood cell transfusions . Poster presented at the American Society of Hematology (ASH) Annual Meeting & Exposition; December 8, 2024. San Diego, CA.
Grivas P, Barata P, Moon H, Gupta S, Hutson T, Sternberg CN, Brown JR, Dave V, Downey C , Shillington AC, Katzenstein HM, Kirker M, Hanson S, Liu FX, Morris V, Bhanegaonkar A, Sonpavde GP. Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the Real-world US PATRIOT-II Study . Clin Genitourin Cancer. 2024 Dec;22(6):102238. doi: 10.1016/j.clgc.2024.102238
Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Wang J , Zhou X , Gnanasakthy A , Taylor K, Yusuf A, Maher I, Jamotte A, Kang YK. Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer . ESMO gastrointestinal oncology. 2024 Dec;6. doi: 10.1016/j.esmogo.2024.100095
Druce KL , Yimer BB, Humphreys J, Njuki LN, Bourke D, Li M, Ellis B, Zhang Y, Bravo R, Hyrich KL, Verstappen SMM, Dixon WG, McBeth J. The epidemiology of psoriatic arthritis in the UK: a health intelligence analysis of UK primary care electronic health records 1991-2020 . Rheumatology. 2024 Dec 1;63(12):3346-52. doi: 10.1093/rheumatology/kead586
Howard-Anderson JR, Brown M, Korn RE, Miller J, Norman Sutton K , Ruffin F, Thomas S, Obi EN, Sidduri N, Watanabe AH, Yucel E, Bosworth H, Boucher H, Collyar D, Doernberg SB, Oakes M, Reeve BB, Fowler VG, King H. Comparing patient and clinician perceptions of health-related quality of life in hospitalized patients with complicated urinary tract infections: a qualitative descriptive study . Poster presented at the IDWeek 2024; October 18, 2024. Los Angeles, CA.
van der Veer SN, Griffiths-Jones D, Parkes M, Druce KL , Amlani-Hatcher P, Armitage CJ, Bansback N, Bower P, Dowding D, Ellis B, Firth J, Gavan S, Mackey E, Sanders C, Sharp CA, Staniland K, Dixon WG, REMORA team. Remote monitoring of rheumatoid arthritis (REMORA): study protocol for a stepped wedge cluster randomized trial and process evaluation of an integrated symptom tracking intervention . Trials. 2024 Oct 15;25(1):683. doi: 10.1186/s13063-024-08497-9
Percy AK, Neul JL, Benke TA, Berry-Kravis EM, Glaze DG, Marsh ED, Barrett AM , An D, Bishop KM, Youakim JM. Trofinetide for the treatment of Rett syndrome: long-term safety and efficacy results of the 32-month, open-label LILAC-2 study . Med. 2024 Oct 11;5(10):1275-1281. doi: 10.1016/j.medj.2024.06.007
Blauvelt A, Reckleff J, Zhao Y, Clark M , Kosa K , Harris N , Esfandiari E, Martin S , Whalley D , Emma GY. Content evaluation of pruritus, skin pain and sleep disturbance patient-reported outcome measures for adolescents and adults with moderate-to-severe atopic dermatitis: qualitative interviews . Br J Dermatol. 2024 Oct 4. doi: 10.1093/bjd/ljae346
Yap C, Aiyegbusi OL, Alger E, Basch E, Bell J, Bhatnagar V, Cella D, Collis P, Dueck AC, Gilbert A, Gnanasakthy A , Greystoke A, Hansen AR, Kamudoni P, Kholmanskikh O, King-Kallimanis BL, Krumbolz H, Minchom A, O'Connor D, Petrie J, Piccinin C, Rantell KR, Rauz S, Retzer A, Rizk S, Wagner L, Sasseville M, Seymour LK, Weber HA, Wilson R, Calvert M, Peipert JD. Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials – insights from an expert virtual roundtable . EClinicalMedicine. 2024 Oct;76:102838. doi: 10.1016/j.eclinm.2024.102838